CMS is increasing the importance of patient-reported health outcomes and adding medication-safety measures, potentially shifting quality priorities for participating Medicare Advantage physicians.

Physicians participating in Medicare Advantage could face changing quality expectations as federal regulators give greater weight to patient-reported health outcomes and introduce new medication-safety measures in the 2027 Medicare Advantage and Part D Star Ratings.

The Centers for Medicare & Medicaid Services (CMS) released the ratings October 8, establishing updated performance assessments for Medicare Advantage and Part D contracts.

For San Diego independent physician associations (IPAs) and medical groups, the changes raise questions about how insurers may adjust clinical performance priorities, reporting expectations, and physician incentive arrangements.

CMS reported that 188 of 508 rated Medicare Advantage prescription drug (MA-PD) contracts, approximately 37%, earned at least four stars for 2027, down from roughly 44% in 2026.

However, approximately 71% of current MA-PD enrollment is in contracts receiving four or more stars. The enrollment-weighted average rating declined slightly, from 4.01 in 2026 to 3.99 in 2027.

These figures measure different things: the percentage of rated contracts and the percentage of beneficiaries enrolled in those contracts.

The changes do not necessarily indicate declining clinical quality. CMS recalculates performance thresholds annually, and changes in measurement methodology can influence contract ratings.

CMS increased the weighting of two patient-reported measures—Improving or Maintaining Physical Health and Improving or Maintaining Mental Health—from one to three following revisions to their specifications.

The agency also introduced two medication-safety measures: Concurrent Use of Opioids and Benzodiazepines and Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults. Each carries a weight of one, compared with the weight of three assigned to the revised patient-reported health outcome measures.

CMS also replaced the previous colorectal cancer screening measure with a respecified version and restored the Care for Older Adults — Functional Status Assessment measure after substantive specification changes. Both carry a weight of one.

These changes increase the relative importance of patient-reported outcomes while adding measures addressing medication safety, preventive screening, and functional health.

For physicians, the measures intersect with prescribing decisions, medication reviews, chronic disease management, and documentation of patients' health status.

Medicare Advantage Star Ratings influence insurers' quality-related financial incentives. Plans receiving higher ratings may qualify for quality bonus payments and associated financial benefits.

Medicare Advantage quality bonus payments go to eligible Medicare Advantage organizations, not directly to physicians. Any resulting changes in physician compensation or performance incentives depend on the terms of individual payer contracts.

As insurers respond to the revised measures, they may adjust quality improvement programs involving contracted physician groups.

However, the federal ratings do not automatically impose new reporting obligations on individual physicians or require insurers to modify existing contracts.

The 2027 Star Ratings are available during Medicare open enrollment, October 15 through December 7, 2026, and will affect Medicare Advantage quality bonus payments in 2028.

San Diego IPAs and medical groups may want to compare the 2027 Star Ratings of their contracted Medicare Advantage plans with prior-year results, review the newly weighted clinical measures, and determine whether existing payer agreements link physician incentives to those measures.

Medical groups may also want to assess their capabilities for medication review, patient-reported outcome measurement, and preventive care tracking.

The national CMS release does not establish how San Diego physician networks will be affected. That requires analysis of local plan ratings and individual contracting arrangements.

The new ratings signal changing federal quality priorities, but their financial and operational effects on independent physicians remain uncertain.